MC-Val-Cit-PAB-clindamycin
Code | Size | Price |
---|
TAR-T18322-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T18322-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
CAS:
1639793-13-7
Molecular Weight:
980.63
Purity:
0.98
SMILES:
C(N[C@H]([C@H](C)Cl)[C@]1(O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[H])(=O)[C@H]2[N+](CC3=CC=C(NC([C@@H](NC([C@@H](NC(CCCCCN4C(=O)C=CC4=O)=O)[C@H](C)C)=O)CCCNC(N)=O)=O)C=C3)(C)C[C@H](CCC)C2
References
Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.